3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Bortezomib
20
Blood Specimen Collection
9
Surveys and Questionnaires
8
Lenalidomide
8
Dexamethasone
8
pomalidomide
6
daratumumab
6
Flow Cytometry
6
Immunoenzyme Techniques
5
Biopsy
5
plerixafor
4
idecabtagene vicleucel
4
carfilzomib
4
Standard of Care
4
Polymerase Chain Reaction
4
Amplified Fragment Length Polymorphism Analysis
4
Specimen Handling
3
Psychiatric Rehabilitation
3
Patient Reported Outcome Measures
3
Microarray Analysis
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Interviews as Topic
3
Drug Therapy
3
Data Collection
3
Cytogenetic Analysis
3
Chromatin Immunoprecipitation Sequencing
3
talquetamab
2
selinexor
2
belantamab mafodotin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Tinzaparin
×
Plasma cell
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled